Most growth hormone peptides sold by clinics and online vendors have thin clinical evidence behind them for body composition. The marketing runs well ahead of the data. There is one notable exception, a peptide with a real FDA approval and real trial evidence for reducing a specific and dangerous kind of fat: tesamorelin.
Tesamorelin is not a household name, and its approved use is narrow. But the mechanism behind it and the data supporting it have implications that reach beyond the population it was approved for. For the professional carrying stubborn abdominal fat that resists diet and training, understanding what tesamorelin is (and what it is not) is worth the time.
What Tesamorelin Is
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). GHRH is the natural signal your hypothalamus sends to your pituitary gland to prompt the release of growth hormone. Tesamorelin mimics that signal, stimulating the pituitary to release the body’s own growth hormone in a natural, pulsatile pattern.
This is an important distinction from injecting growth hormone directly. Tesamorelin does not supply growth hormone from outside. It prompts your own pituitary to release more of yours. That approach tends to preserve the body’s natural feedback regulation better than direct growth hormone injection, which is part of why GHRH analogs are of interest in optimization medicine.
Tesamorelin is FDA-approved and sold under the brand name Egrifta. That approval matters, because it means the molecule went through the full clinical trial and regulatory process, unlike most peptides marketed for body composition.
The Approved Use and Why It Matters
Tesamorelin’s FDA approval is for the reduction of excess visceral abdominal fat in people with HIV-associated lipodystrophy, a condition where fat redistributes to the abdomen in a specific and metabolically harmful pattern.
Here is why that approval is relevant well beyond that population. The approval was granted because tesamorelin demonstrably reduced visceral adipose tissue in clinical trials. Visceral fat is the deep abdominal fat that surrounds the organs, and it is the metabolically dangerous kind, associated with insulin resistance, inflammation, and cardiovascular risk. The mechanism by which tesamorelin reduces visceral fat is not specific to HIV. It works through growth hormone’s effects on fat metabolism, which operate the same way in anyone carrying excess visceral fat.
So the approval is for a narrow population, but the biology it validated is general. That is the foundation for the off-label interest in tesamorelin for visceral fat in other patients.
The Trial Data
The clinical trials that supported tesamorelin’s approval, led by Falutz and colleagues, measured visceral adipose tissue directly using CT imaging, which is a rigorous way to quantify this specific fat depot rather than relying on weight or waist measurement alone.
The trials demonstrated meaningful reductions in visceral adipose tissue in the treated group compared to placebo. They also showed effects on lipid profiles, with improvements in certain markers. The visceral fat reduction was the primary finding and the basis for approval.
This is a stronger evidence base than exists for most peptides marketed for fat loss. When a clinic or vendor claims a growth hormone peptide “melts belly fat,” ask what the evidence is. For most peptides, the honest answer is that the evidence is thin. For tesamorelin, there is actual trial data measuring the actual fat depot with actual imaging. That distinction is the whole point of this post.
Why Visceral Fat Deserves Special Attention
Not all fat is equal, a theme we developed in the post on why BMI is a bad metric. Subcutaneous fat, the fat under the skin, is relatively benign. Visceral fat, packed around the organs in the abdomen, is the dangerous kind.
Visceral fat is metabolically active in harmful ways. It releases inflammatory signals, drives insulin resistance, and is strongly associated with cardiovascular disease and type 2 diabetes. Two people at the same weight can have very different amounts of visceral fat and therefore very different health risks.
The “executive belly,” the firm abdominal fat that a lean-limbed professional carries despite reasonable diet and exercise, is often substantially visceral. It is also the fat that responds least to conventional approaches, because it is driven partly by hormonal and metabolic factors rather than simple caloric excess. This is the fat pattern where tesamorelin’s mechanism becomes relevant.
The Off-Label Clinical Use
Because tesamorelin’s mechanism is not specific to HIV-associated lipodystrophy, it has drawn interest for off-label use in other patients with excess visceral fat and appropriate clinical profiles. Off-label prescribing (using an approved drug for a use other than its approved indication) is legal and common in medicine when a physician judges it appropriate.
The appropriate candidate is not “anyone who wants to lose belly fat.” Tesamorelin is a serious medication with real considerations, and it is suited to specific patients: those with significant visceral adiposity, appropriate metabolic context, and no contraindications, who are monitored properly. It is not a shortcut that replaces the foundations of body composition, which remain nutrition, resistance training, sleep, and addressing underlying hormonal and metabolic dysfunction.
It is also worth noting the regulatory reality. As an FDA-approved drug, brand-name Egrifta is available but expensive. Compounded versions of tesamorelin exist through licensed pharmacies, and their availability intersects with the broader peptide regulatory landscape we covered in the post on the FDA peptide crackdown. The specifics of sourcing and cost are part of the clinical conversation.
How It Compares to Other Growth Hormone Peptides
Tesamorelin sits alongside other GHRH analogs like sermorelin and CJC-1295, which we compare in detail in the post on sermorelin, ipamorelin, and CJC-1295. The key difference is the depth of clinical evidence.
Tesamorelin has FDA approval and rigorous trial data measuring visceral fat specifically. Sermorelin has a long history of use and a prior FDA approval for a different purpose, but its evidence for body composition specifically is more limited. CJC-1295 and the ghrelin-pathway peptides have less rigorous human data still.
This does not mean the others have no role. It means that when the specific goal is visceral fat reduction backed by the strongest evidence, tesamorelin is the peptide with the actual data. For other goals, the calculus may differ.
Monitoring and the IGF-1 Question
Any growth hormone peptide requires monitoring, and tesamorelin is no exception. The central marker is IGF-1 (insulin-like growth factor 1), which reflects growth hormone activity in the body.
When you stimulate growth hormone release, IGF-1 rises. This is expected and is part of how the treatment works. The clinical task is to keep IGF-1 in an appropriate range, not to push it as high as possible. Excessively elevated IGF-1 over time raises theoretical concerns, including around cancer surveillance, because IGF-1 is a growth signal. This is a conversation that has to be had honestly with any patient considering growth hormone peptides.
Monitoring also includes glucose and insulin, because growth hormone can affect glucose metabolism, and patients with insulin resistance need particular attention. Side effect surveillance covers injection site reactions, fluid retention, joint discomfort, and other effects. This is not a set-it-and-forget-it treatment. It requires baseline labs, follow-up testing, and ongoing clinical judgment.
Contraindications matter too. Active cancer or a significant cancer history, certain pituitary conditions, and other factors can make growth hormone peptides inappropriate. A proper evaluation screens for these before treatment.
Who Is and Is Not a Candidate
A reasonable candidate for a conversation about tesamorelin has significant visceral fat, an appropriate metabolic and health profile, no contraindications, and a willingness to be monitored. The treatment fits into a broader plan rather than standing alone.
Not appropriate candidates include people looking for a quick fix without addressing the foundations, people with contraindications like active malignancy, and people who would be better served by starting with hormone optimization, structured weight management, and lifestyle changes that have not yet been tried. For many patients, the visceral fat that concerns them will respond to addressing insulin resistance and hormonal imbalances directly, which is where the evaluation usually starts. This connects to the metabolic picture we covered in the post on HbA1c and the insulin connection and the broader weight management therapy program.
How We Approach Tesamorelin
At Towsen Clinic, tesamorelin is considered within the context of a full metabolic and hormonal evaluation, not offered as a standalone belly-fat solution. The candidate has to fit the profile, the monitoring has to be in place, and the treatment has to make sense alongside the foundations of good body composition. The peptide approach is detailed on the advanced peptide therapy page.
If you carry stubborn visceral fat and want to understand whether tesamorelin is a reasonable part of your plan, schedule a consultation and we will evaluate your full picture and whether this specific tool fits.
